La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

CymaBay Therapeutics Croissance future

Future contrôle des critères 2/6

CymaBay Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 54.8% et de 50.9% par an respectivement. Le BPA devrait croître de de 54.5% par an. Le rendement des capitaux propres devrait être -50.1% dans 3 ans.

Informations clés

54.8%

Taux de croissance des bénéfices

54.5%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.6%
Taux de croissance des recettes	50.9%
Rendement futur des capitaux propres	-50.1%
Couverture par les analystes	Good
Dernière mise à jour	29 Feb 2024

Mises à jour récentes de la croissance future

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:CBAY - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	274	-46	11	21	7
12/31/2025	115	-158	-97	-116	8
12/31/2024	2	-175	-181	-160	4
12/31/2023	31	-105	-73	-73	N/A
9/30/2023	31	-90	-64	-64	N/A
6/30/2023	31	-81	-56	-55	N/A
3/31/2023	N/A	-107	-53	-52	N/A
12/31/2022	N/A	-106	-84	-84	N/A
9/30/2022	N/A	-106	-80	-80	N/A
6/30/2022	N/A	-104	-78	-77	N/A
3/31/2022	N/A	-100	-74	-74	N/A
12/31/2021	N/A	-90	-70	-69	N/A
9/30/2021	N/A	-79	-70	-70	N/A
6/30/2021	N/A	-68	-62	-62	N/A
3/31/2021	N/A	-55	-51	-51	N/A
12/31/2020	N/A	-51	-45	-45	N/A
9/30/2020	N/A	-65	-58	-58	N/A
6/30/2020	N/A	-80	-74	-74	N/A
3/31/2020	N/A	-93	-90	-90	N/A
12/31/2019	N/A	-103	-98	-98	N/A
9/30/2019	N/A	-93	-90	-89	N/A
6/30/2019	N/A	-85	-83	-82	N/A
3/31/2019	N/A	-79	-72	-71	N/A
12/31/2018	N/A	-73	-55	-55	N/A
9/30/2018	5	-58	-41	-41	N/A
6/30/2018	5	-48	-31	-31	N/A
3/31/2018	5	-39	-24	-24	N/A
12/31/2017	10	-28	-20	-20	N/A
9/30/2017	5	-29	N/A	-19	N/A
6/30/2017	5	-27	N/A	-19	N/A
3/31/2017	5	-25	N/A	-19	N/A
12/31/2016	N/A	-27	N/A	-23	N/A
9/30/2016	N/A	-26	N/A	-23	N/A
6/30/2016	N/A	-26	N/A	-24	N/A
3/31/2016	N/A	-20	N/A	-23	N/A
12/31/2015	N/A	-16	N/A	-23	N/A
9/30/2015	N/A	-22	N/A	-26	N/A
6/30/2015	N/A	-22	N/A	-23	N/A
3/31/2015	N/A	-24	N/A	-22	N/A
12/31/2014	N/A	-32	N/A	-21	N/A
9/30/2014	N/A	208	N/A	-17	N/A
6/30/2014	N/A	257	N/A	-14	N/A
3/31/2014	N/A	240	N/A	-11	N/A
12/31/2013	N/A	244	N/A	-8	N/A
9/30/2013	0	11	N/A	-5	N/A
6/30/2013	3	-36	N/A	-8	N/A
3/31/2013	3	-23	N/A	-10	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CBAY devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CBAY devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CBAY devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CBAY ( 50.9% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CBAY ( 50.9% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: CBAY devrait être non rentable dans 3 ans.

CymaBay Therapeutics Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

No longer forecast to breakeven

Price target increased by 8.5% to US$31.07

Forecast to breakeven in 2026

Price target increased by 7.5% to US$24.82

Price target increased by 17% to US$21.27

Consensus revenue estimates increase by 156%

Recent updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Price target increased by 8.5% to US$31.07

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

Forecast to breakeven in 2026

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

Cymabay Therapeutics, Inc. Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

Price target increased by 7.5% to US$24.82

New minor risk - Profitability

CymaBay Therapeutics, Inc. Announces Publication of Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President exercised options and sold US$597k worth of stock

General Counsel notifies of intention to sell stock

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999939 million.

Price target increased by 17% to US$21.27

Insider notifies of intention to sell stock

Consensus revenue estimates increase by 156%

Price target increased by 8.0% to US$17.64

New minor risk - Profitability

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates fall by 15%

Price target increased by 8.5% to US$15.56

Insider notifies of intention to sell stock

Price target increased by 8.2% to US$14.67

New minor risk - Share price stability

Insider notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Consensus revenue estimates fall by 40%

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. Appoints Harish Shantharam as Chief Financial Officer

Executive Officer notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Price target increased by 11% to US$13.56

Price target increased by 8.1% to US$11.63

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999785 million.

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Cymabay Completes Enrollment for the Response Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from Russell 2000 Dynamic Index

CymaBay Therapeutics, Inc. Presents Positive PBC Data at the International Liver Congress 2022

President recently bought US$100k worth of stock

CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Price target decreased to US$10.50

Insufficient new directors

CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nominating and Corporate Governance Committee of the Board

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?

Chief Medical Officer recently bought US$61k worth of stock

Why I've Taken A 'Starter' Position In CymaBay Therapeutics

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Cymabay Therapeutics, Inc. Announces Positive Data from Its Previously Completed Phase 2 Study and the Enhance Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis

We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

Independent Director has left the company

Price target decreased to US$12.00

CymaBay Therapeutics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

New 90-day low: US$5.32

We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely